SynthesisHead and neck pathology2025
Clinicopathological Profile of HPV-related Multiphenotypic Sinonasal Carcinoma: A Systematic Review.
Synthesis in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Characterization of CD8 + and CD68 + Microenvironment and PDL1 Expression in HPV-related Multiphenotypic Sinonasal Carcinoma.Head and neck pathology · 2026Article
- HPV-positive cancers at uncommon sites: a narrative review.Oncology reviews · 2026Review
- Case Reports of Four Patients with HPV-Positive Head and Neck Cancer of Non-Oropharyngeal Origin Undergoing Liquid Biopsy for Circulating Cell-Free HPV-DNA before, during, and after Treatment.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeThis study aimed to perform a systematic review of the clinicopathological, prognostic features, and HPV genotyping patterns of HPV-related multiphenotypic sinonasal carcinoma (HMSC).
methodsThis study adhered to the PRISMA 2020 guidelines and was registered in the PROSPERO database. We included case reports, case series studies, and cohort studies of HMSC indexed in the PubMed, Web of Science, Scopus, Embase, and LILACS databases published between 2017 and 2025. Collected variables were analyzed descriptively, followed by association analyses using Fisher's and Chi-squared tests, and the Kaplan-Meier method. The quality assessment of the included studies was conducted using the Joanna Briggs Institute tools.
resultsThis systematic review identified 32 studies encompassing 101 HMSC cases. The majority occurred in the nasal cavity of patients in the sixth decade of life, without significant sex predilection. Microscopically, the HMSC predominantly displayed basaloid morphology with solid and cribriform growth patterns, high mitotic activity, pleomorphism, and necrosis. Most patients underwent surgical excision and experienced no recurrence or metastasis, indicating favorable outcomes. However, treatment modality, recurrence, and distant metastasis negatively affected survival rates. HMSC cases showed strong p16 expression, variable squamous/epithelial and myoepithelial marker expression, and a high Ki67 index. HPV 33 was the most prevalent type identified.
conclusionHMSC is a heterogeneous malignant lesion with excellent overall prognosis. Detection of transcriptionally active HPV through in situ hybridization or reverse transcriptase polymerase chain reaction is critical for definitive diagnosis of HMSC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.